

PRELIMINARY NOVEMBER 2015 THERAPEUTIC DRUG CLASS

ANTI-HISTAMINES, MINIMALLY SEDATING
BRONCHODILATORS, BETA AGONIST
COPD AGENTS
GLUCOCORTICOIDS, INHALED
GLUCOCORTICOIDS, ORAL
LEUKOTRIENE MODIFIERS
COUGH AND COLD/NARCOTICS
EPINEPHRINE, SELF-INJECTED
INTRANASAL RHINITIS AGENTS
ANTI-HYPERTENSIVES, SYMPATHOLYTIC
ANTI-HYPERURICEMICS, ORAL
BILE SALTS
ERYTHROPOIESIS STIMULATING PROTEINS
HISTAMINE II RECEPTOR BLOCKERS
OPHTHALMIC ANTIBIOTIC/STEROID COMBINATIONS
OPHTHALMIC ANTIBIOTICS
OPHTHALMIC ANTI-INFLAMMATORIES
OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS
OPHTHALMICS, GLAUCOMA AGENTS
OTIC ANTIBIOTICS
OTIC ANTI-INFECTIVES
ANTIPSORIATICS, ORAL
ANTIPSORIATICS, TOPICAL
IMMUNOMODULATORS FOR ATOPIC DERMATITIS
IMMUNOMODULATORS, TOPICAL
STERIODS, TOPICAL-LOW POTENCY
STERIODS, TOPICAL-MEDIUM POTENCY
STERIODS, TOPICAL-HIGH POTENCY
STERIODS, TOPICAL-VERY HIGH POTENCY
CYTOKINE AND CAM ANTAGONISTS
NSAIDS
NEUROPATHIC PAIN (ANALGESICS/ANESTHETICS TOPICAL AND FIBROMYALGIA)
ALZHEIMER'S AGENTS
ANTICONVULSANTS
ANTIDEPRESSANTS, OTHER
ANTIDEPRESSANTS, SSRI's
ANTIPARKINSON'S AGENTS
ANTIPSYCHOTICS
ANXIOLYTICS
SEDATIVE HYPNOTICS
STIMULANTS AND RELATED AGENTS

POTENTIAL NEW CLASSES

IDIOPATHIC PULMONARY FIBROSIS
METHOTREXATE